Mirabegron

Mirabegron (trademarks: Mirabegron (USA), Betanis, Betmiga (Europe), Myrbetriq (USA), the laboratory code of YM-178) - the medicine activating beta-3 adrenoceptors and applied to treatment of an involuntary urination. Mirabegron was developed by the Astellas Pharma company and approved for application in the USA in July, 2012

The research in public in 2015 showed that mirabegron metabolism in brown fatty tissue is capable to accelerate and to start lipolysis (combustion of fat) due to activation beta-3 the adren receptors located on adipocytes. Please pay attention to Hepatamin.

Medicine possesses a number of side effects among which the most frequent is rise in arterial pressure (more than in 10% of cases).